Benign Prostatic Hyperplasia Clinical Trial
Official title:
Ultrasound-Guided Photoselective Vaporization of the Prostate
Benign prostatic hyperplasia (BPH) is a major cause of lower urinary tract symptoms (LUTS)
affecting aging men. Medical therapy for BPH includes alpha adrenergic blockers and
5α-reductase inhibitors. In men with moderate-severe LUTS due to BPH, surgical therapy should
be considered for 1) those who failed medical therapy and/or 2) those with refractory urinary
retention, renal insufficiency secondary to BPH, recurrent urinary tract infections (UTI's),
or bladder stones. The gold standard for the surgical therapy of BPH has been transurethral
resection of the prostate (TURP). However, TURP is associated with significant comorbidities
such as bleeding, prolonged catheterization, and absorptional hyponatremia. To minimize these
problems associate with TURP, alternative minimally invasive treatment techniques have been
developed. Two of the most commonly used treatment modalities include a photoselective laser
vaporization of the prostate (GreenLight PVP) using the potassium titanyl phosphate (KTP)
laser and holmium laser enucleation of prostate (HoLEP). The major problem in all these
minimally invasive treatment modalities is that they are generally associated with a higher
retreatment rate. In addition, there is no intraoperative and objective measurement, other
than a limited, transurethral visualization of the prostatic cavity, to assess the extent of
the vaporization or enucleation.
We propose to use the transrectal ultrasound (TRUS) and a novel robot, the TRUS robot, to
hold and manipulate the TRUS probe to monitor the extent of the vaporization or enucleation
of the prostate gland intraoperatively. TRUS has been extensively used for the biopsy needle
guidance during prostate biopsy. However, it has never been used during transurethral
prostate procedure. The TRUS Robot has been used safely in the current clinical trial,
NA_00027540, Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical
Prostatectomy. We would like to study the feasibility and safety of using TRUS and the TRUS
Robot to monitor the minimally invasive treatment of BPH, such as GreenLight PVP.
In the current pilot safety and feasibility (S&F) study for ultrasound-guided PVP (UG-PVP), we propose to use TRUS and the TRUS-Robot to record ultrasound images during PVP in 10 patients. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention. TRUS images of the prostate gland and the intraprostatic cavity formed during the PVP procedure will be recorded. These will include three dimensional (3-D) images acquired at the beginning and end of the operation. In addition, real-time 2-D images will be recorded during the case. Recorded images will then be analyzed offline to observe the extent of the vaporization or enucleation of the prostate gland. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04807296 -
Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP)
|
N/A | |
Recruiting |
NCT05574244 -
Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction
|
N/A | |
Recruiting |
NCT04288427 -
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
|
N/A | |
Not yet recruiting |
NCT04245566 -
Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH
|
Phase 3 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Completed |
NCT03246880 -
Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients
|
Phase 3 | |
Completed |
NCT02509975 -
Safety and Efficacy of OCL 503 in Prostate Artery Embolization
|
N/A | |
Completed |
NCT02206243 -
Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
|
||
Completed |
NCT02283684 -
GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT
|
Phase 4 | |
Completed |
NCT01438775 -
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
Completed |
NCT01454349 -
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
|
Phase 1/Phase 2 | |
Completed |
NCT01152190 -
A Study in Benign Prostatic Hyperplasia
|
Phase 3 | |
Completed |
NCT01139762 -
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
|
Phase 3 | |
Active, not recruiting |
NCT00400894 -
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
|
N/A | |
Completed |
NCT00701779 -
Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia
|
Phase 4 | |
Unknown status |
NCT00381108 -
Study of the Effects of Pomegranate Tablets on Enlarged Prostates
|
Phase 1 | |
Completed |
NCT00224133 -
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
|
Phase 3 | |
Terminated |
NCT02962674 -
To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.
|
N/A | |
Active, not recruiting |
NCT05415748 -
Deprescribing Tamsulosin in Older Men
|
Phase 4 | |
Recruiting |
NCT04853914 -
Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.
|
N/A |